NICE recommends sunitinib (Sutent) for the first-line treatment of metastatic renal cancer
NICE (UK) recommends the tyrosine kinase inhibitor sunitinib (Sutent) first line treatment of metastatic renal cell carcinoma. Implications for patients that are on immunotherapy